Cleaved NOTCH1 expression pattern in head and neck squamous cell carcinoma is associated with NOTCH1 mutation, HPV status, and high-risk features

Cancer Prevention Research

Volumn 8, Issue 4, 2015, Pages 287-295

  Rettig, Eleni M ^a   Chung, Christine H ^a,b   Bishop, Justin A ^a   Howard, Jason D ^a   Sharma, Rajni ^a   Li, Ryan J ^a   Douville, Christopher ^c   Karchin, Rachel ^a,c   Izumchenko, Evgeny ^a   Sidransky, David ^a   Koch, Wayne ^a   Califano, Joseph ^a,d   Agrawal, Nishant ^a   Fakhry, Carole ^a,d,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d GREATER BALTIMORE MEDICAL CENTER   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOTCH1 INTRACELLULAR DOMAIN; NOTCH1 RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG; NOTCH1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER OF UNKNOWN PRIMARY SITE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH RISK PATIENT; HUMAN; HYPOPHARYNX CARCINOMA; IMMUNOHISTOCHEMISTRY; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; MUTATION; ONCOLOGICAL PARAMETERS; OROPHARYNX CARCINOMA; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; PAPILLOMAVIRIDAE; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TUMOR INVASION; TUMOR RECURRENCE; VIROLOGY;

BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RECEPTOR, NOTCH1; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84927671117     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0366     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Gillison ML, D'SouzaG,Westra W, Sugar E, Xiao W, Begum S, et al. Distinct risk factor profi les for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008;100:407-20.
3. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345:1890-900.
4. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011;333:1154-7.
5. Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333:1157-60.
6. Seiwert TY, Zuo Z, Keck MK, Khattri A, Pedamallu CS, Stricker TP, et al. Integrative and comparative genomic analysis of HPV-positive and HPVnegative head and neck squamous cell carcinomas. Clin Cancer Res 2015;21:632-41.
7. Loyo M, Li RJ, Bettegowda C, Pickering CR, Frederick MJ, Myers JN, et al. Lessons learned from next-generation sequencing in head and neck cancer. Head Neck 2013;35:454-63.
8. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.
9. Pickering CR, Zhang J, Yoo SY, Bengtsson L, Moorthy S, Neskey DM, et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 2013;3:770-81.
10. Sun W, Gaykalova DA, Ochs MF, Mambo E, Arnaoutakis D, Liu Y, et al. Activation of the NOTCH pathway in head and neck cancer. Cancer Res 2014;74:1091-104.
11. Egloff AM, Grandis JR. Molecular pathways: context-dependent approaches to Notch targeting as cancer therapy. Clin Cancer Res 2012;18: 5188-95.
12. Louvi A, Artavanis-Tsakonas S. Notch and disease: a growing field. Semin Cell Dev Biol 2012;23:473-80.
13. Dotto GP. Notch tumor suppressor function. Oncogene 2008;27:5115-23.
14. Sakamoto K, Fujii T, Kawachi H, Miki Y, Omura K, Morita K, et al. Reduction of NOTCH1 expression pertains to maturation abnormalities of keratinocytes in squamous neoplasms. Lab Invest 2012;92:688-702.
15. Li D, Dong P, Wu C, Cao P, Zhou L. Notch1 overexpression associates with poor prognosis in human laryngeal squamous cell carcinoma. Ann Otol Rhinol Laryngol 2014;123:705-10.
16. Lin JT, Chen MK, Yeh KT, Chang CS, Chang TH, Lin CY, et al. Association of high levels of Jagged-1 and Notch-1 expressionwith poor prognosis in head and neck cancer. Ann Surg Oncol 2010;17:2976-83.
17. Joo YH, Jung CK, Kim MS, Sun DI. Relationship between vascular endothelial growth factor and Notch1 expression and lymphatic metastasis in tongue cancer. Otolaryngol Head Neck Surg 2009;140:512-8.
18. Gu F, Ma Y, Zhang Z, Zhao J, Kobayashi H, Zhang L, et al. Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 2010;23:671-6.
19. Zhang ZP, Sun YL, Fu L, Gu F, Zhang L, Hao XS. Correlation of Notch1 expression and activation to cisplatin-sensitivity of head and neck squamous cell carcinoma. Ai Zheng 2009;28:100-3.
20. Singhi AD, Westra WH. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010;116:2166-73.
21. Kluk MJ, Ashworth T, Wang H, Knoechel B, Mason EF, Morgan EA, et al. Gauging NOTCH1 activation in cancer using immunohistochemistry. PLoS ONE 2013;8:e67306.
22. Boukamp P, Stanbridge EJ, Foo DY, Cerutti PA, Fusenig NE. c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res 1990;50:2840-7.
23. Fertig EJ, Ren Q, Cheng H, Hatakeyama H, Dicker AP, Rodeck U, et al. Gene expression signatures modulated by epidermal growth factor receptor activation and their relationship to cetuximab resistance in head and neck squamous cell carcinoma. BMC Genomics 2012;13:160.
24. Qiu W, Schonleben F, Li X, Ho DJ, Close LG, Manolidis S, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 2006;12:1441-6.
25. Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, et al. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 2010;32:417-26.
26. Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, et al. Predicting survival in head and neck squamous-cell carcinoma from TP53 mutation. Hum Genet. 2014 Aug 10. [Epub ahead of print].
27. Leong KG, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I, et al. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 2007;204: 2935-48.
28. Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 2011;307:26-36.
29. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004;64:6854-7.
30. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 2003;33: 416-21.
31. Demehri S, Turkoz A, Kopan R. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. Cancer Cell 2009;16:55-66.
32. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 2011;11:338-51.
33. Howard JD, Moriarty WF, Park J, Riedy K, Panova IP, Chung CH, et al. Notch signalingmediates melanoma-endothelial cell communication and melanoma cell migration. Pigment Cell Melanoma Res 2013;26:697-707.
34. Charles N, Ozawa T, Squatrito M, Bleau AM, Brennan CW, Hambardzumyan D, et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. Cell Stem Cell 2010;6:141-52.
35. Lu J, Ye X, Fan F, Xia L, Bhattacharya R, Bellister S, et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell 2013;23:171-85.
36. Aster JC, Blacklow SC. Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J Clin Oncol 2012;30:2418-20.
37. Weng AP, Ferrando AA, LeeW, Morris JPt, Silverman LB, Sanchez-IrizarryC, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-71.
38. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, et al. TAN- 1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991; 66:649-61.
39. Klinakis A, Lobry C, Abdel-Wahab O, Oh P, HaenoH, Buonamici S, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature 2011;473:230-3.
40. Kagawa S,NatsuizakaM, Whelan KA, FacompreN,Naganuma S,Ohashi S, et al. Cellular senescence checkpoint function determines differential Notch1-dependent oncogenic and tumor-suppressor activities. Oncogene. 2014 Jun 16. [Epub ahead of print].
41. Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005;8: 13-23.
42. Felician G, Collesi C, Lusic M, Martinelli V, Dal Ferro M, Zentilin L, et al. Epigenetic modi fication at Notch responsive promoters blunts effi cacy of inducing Notch pathway reactivation after myocardial infarction. Circ Res 2014;115:636-49.
43. Wu L, Griffin JD. Modulation of Notch signaling by mastermind-like (MAML) transcriptional co-activators and their involvement in tumorigenesis. Semin Cancer Biol 2004;14:348-56.
44. Talora C, Sgroi DC, Crum CP, Dotto GP. Specific down-modulation of Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/ E7 expression and late steps of malignant transformation. Genes Dev 2002;16:2252-63.
45. Talora C, Cialfi S, Segatto O, Morrone S, Kim Choi J, Frati L, et al. Constitutively active Notch1 induces growth arrest of HPV-positive cervical cancer cells via separate signaling pathways. Exp Cell Res 2005;305:343-54.
46. Weijzen S, Zlobin A, Braid M, Miele L, Kast WM. HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J Cell Physiol 2003;194:356-62.
47. Yugawa T, Handa K, Narisawa-Saito M, Ohno S, Fujita M, Kiyono T. Regulation of Notch1 gene expression by p53 in epithelial cells. Mol Cell Biol 2007;27:3732-42.
48. Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolfschoten I, et al. Notch1 is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCK1/2 and MRCKalpha kinases. Genes Dev 2007;21:562-77.
49. Duan L, Yao J, Wu X, Fan M. Growth suppression induced by Notch1 activation involves Wnt-beta-catenin down-regulation in human tongue carcinoma cells. Biol Cell 2006;98:479-90.
50. Dotto GP. Crosstalk of Notch with p53 and p63 in cancer growth control. Nat Rev Cancer 2009;9:587-95.